Optimizing Outcomes for Patients With Curable Bladder Cancer
This video highlights emerging data on genomic markers of response to neoadjuvant chemotherapy for patients with bladder cancer.
In this video, Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center in Philadelphia, discusses highlights of a session on bladder cancer from the 2017 Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.
Dr. Plimack chaired the session, which focused on optimizing outcomes in muscle-invasive bladder cancer, and gave a presentation on genomic markers of response to neoadjuvant chemotherapy. Emerging data on alterations in DNA repair genes and their association with outcomes are informing clinical trial designs with the aim of studying the feasibility of reducing treatment burden for this patient population.
